A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids on Plasma Reproductive Hormones, Fertility, Withdrawal Symptoms and Myocardial Function - The LUCAS Trial
Sponsor: Rigshospitalet, Denmark
Terminated
Lack of recruitment
Other terminated trials from Rigshospitalet, Denmark
Other Hypogonadism trials with similar outcome
This PHASE4 trial investigates Hypogonadism and Hypogonadism, Male and is currently terminated or withdrawn. Rigshospitalet, Denmark leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Feb 2024 — Mar 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Feb 2022 — Feb 2024 [monthly]
Recruiting PHASE4
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rigshospitalet, Denmark
For direct contact, visit the study record on ClinicalTrials.gov .